BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim HY, Cho HK, Choi YH, Lee KS, Cheong J. Bile acids increase hepatitis B virus gene expression and inhibit interferon-α activity: Bile acid metabolism and HBV gene expression. FEBS Journal 2010;277:2791-802. [DOI: 10.1111/j.1742-4658.2010.07695.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Xia Z, Zheng J, Zheng L, Zheng E, Zou Z, Sheng X, Wu J. Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs. Lipids Health Dis 2021;20:148. [PMID: 34717643 DOI: 10.1186/s12944-021-01582-x] [Reference Citation Analysis]
2 Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology. 2011;140:1120-1125.e1-12. [PMID: 21334334 DOI: 10.1053/j.gastro.2011.02.044] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
3 Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Niu Y, Xie W, Qin W. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma. Acta Pharmaceutica Sinica B 2011;1:73-9. [DOI: 10.1016/j.apsb.2011.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Chen W, Xu W. Wnt/β-catenin signaling regulates Helicoverpa armigera pupal development by up-regulating c-Myc and AP-4. Insect Biochemistry and Molecular Biology 2014;53:44-53. [DOI: 10.1016/j.ibmb.2014.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hu Y, Ding YL, Yu L. The impact of intrahepatic cholestasis of pregnancy with hepatitis B virus infection on perinatal outcomes. Ther Clin Risk Manag 2014;10:381-5. [PMID: 24920912 DOI: 10.2147/TCRM.S61530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Geier A. Hepatitis B virus: the “metabolovirus” highjacks cholesterol and bile acid metabolism. Hepatology. 2014;60:1458-1460. [PMID: 24829054 DOI: 10.1002/hep.27224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
8 Niu Y, Xu M, Slagle BL, Huang H, Li S, Guo GL, Shi G, Qin W, Xie W. Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis. Hepatology 2017;65:893-906. [PMID: 28102638 DOI: 10.1002/hep.28924] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Tenge VR, Murakami K, Salmen W, Lin SC, Crawford SE, Neill FH, Prasad BVV, Atmar RL, Estes MK. Bile Goes Viral. Viruses 2021;13:998. [PMID: 34071855 DOI: 10.3390/v13060998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Huang J, Zhao L, Yang P, Chen Z, Ruan XZ, Huang A, Tang N, Chen Y. Fatty acid translocase promoted hepatitis B virus replication by upregulating the levels of hepatic cytosolic calcium. Exp Cell Res 2017;358:360-8. [PMID: 28697919 DOI: 10.1016/j.yexcr.2017.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 12.8] [Reference Citation Analysis]
12 Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int. 2011;31:282-290. [PMID: 21281428 DOI: 10.1111/j.1478-3231.2010.02423.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
13 Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5:1060-1069. [PMID: 24268772 DOI: 10.1016/j.celrep.2013.10.030] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
14 Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology. 2011;53:1476-1485. [PMID: 21520166 DOI: 10.1002/hep.24195] [Cited by in Crossref: 140] [Cited by in F6Publishing: 144] [Article Influence: 14.0] [Reference Citation Analysis]
15 Nemes B, Gámán G, Doros A. Biliary complications after liver transplantation. Expert Rev Gastroenterol Hepatol. 2015;9:447-466. [PMID: 25331256 DOI: 10.1586/17474124.2015.967761] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
16 Shivanna V, Kim Y, Chang KO. The crucial role of bile acids in the entry of porcine enteric calicivirus. Virology 2014;456-457:268-78. [PMID: 24889246 DOI: 10.1016/j.virol.2014.04.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
17 Rattay S, Graf D, Kislat A, Homey B, Herebian D, Häussinger D, Hengel H, Zimmermann A, Schupp AK. Anti-inflammatory consequences of bile acid accumulation in virus-infected bile duct ligated mice. PLoS One 2018;13:e0199863. [PMID: 29953538 DOI: 10.1371/journal.pone.0199863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Rudraiah S, Zhang X, Wang L. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? Annu Rev Pharmacol Toxicol. 2016;56:605-626. [PMID: 26738480 DOI: 10.1146/annurev-pharmtox-010715-103209] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]